New DURO-TUSS™ Chesty Cough Lozenge Flavour is Here

21 May 2010
 Managing both chest congestion and a sore throat has never been easier, as new DURO-TUSS™ Chesty Cough eucalyptus and menthol lozenge joins a broad and ever increasing range of DURO-TUSS™ cough medicine products, just in time for the 2010 Australian winter season.

The new cool flavoured chesty cough lozenge combines two well established active ingredients for effective dual action with mucolytic Bromhexine hydrochloride to clear chest congestion and anti-bacterial Cetylpyridinium chloride to relieve a sore throat associated with a chesty cough.

Arriving in pharmacy now, DURO-TUSS™ Chesty Cough eucalyptus and menthol lozenge in a pack of 24 contains full strength cough medicine in a convenient, portable dose form for those on the go, bringing people even more choice for their chesty cough and sore throat needs.

The new lozenge follows DURO-TUSS™ Chesty Cough lemon flavoured lozenges, which debuted in Australia in 2009 and contain the same full strength active ingredients.

Suitable for adults, children 6 years of age and older and people with diabetes, both over-the-counter lozenge flavours are being supported with a campaign to help pharmacy staff make appropriate recommendations to consumers for these and other DURO-TUSS™ products.

Both DURO-TUSS™ Chesty Cough lozenge flavours are also free of sugar, alcohol, lactose and gluten.

iNova Pharmaceuticals developed DURO-TUSS™ Chesty Cough eucalyptus and menthol lozenges, which are proudly Australian owned and made to the highest manufacturing and quality standards, as is the entire DURO-TUSS™ product range.

DURO-TUSS™ is a cough medicine brand with a longstanding heritage of more than 25 years. Further information on the DURO-TUSS™ range is available at www.inovapharma.com

Contacts:
Media enquiries: Athena Kolivos, iNova Pharmaceuticals – 61 2 412 857 698

DURO-TUSS™ Chesty Cough Lozenge: Actives (per lozenge): Bromhexine HCl 8mg, Cetylpyridinium chloride 1.33mg

Always read the label. Use only as directed. If symptoms persist, see your healthcare professional.

iNova Pharmaceuticals:

iNova Pharmaceuticals (Australia) Pty Limited is an Australian owned and operated pharmaceutical company, and corporate headquarters for iNova Pharmaceuticals (“iNova”) operations across Australia, Asia-Pacific and Southern Africa.

Exporting to over 20 countries, iNova has leading consumer healthcare and prescription product brands with a current portfolio of in-licensed and in-house developed drugs mainly in weight management, pain management, allergy, sexual health, dermatology, cardiology and respiratory health.

iNova has over 50 years heritage from Riker Laboratories and 3M Pharmaceuticals following the November 2006 purchase of 3M’s Asia-Pacific pharmaceutical business by Australian private equity firms Archer Capital and Ironbridge Capital. Many products originally from these companies contribute to iNova’s diverse product range, alongside new ones in-licensed or developed and manufactured at the Sydney iNova Technology Centre.

iNova’s broad capabilities include in-house product development, manufacturing, quality, regulatory, business development and marketing processes to develop, register and make available DURO-TUSS™ and other market leading brands. Consequently, we will continue to introduce new products and make available new formulations and dosage forms as additional line extensions to DURO-TUSS™ and other brands in meeting the therapeutic needs of patients, consumers and providing value.

Further information is available at www.inovapharma.com

DURO-TUSS ™

DURO-TUSS range of products provide effective relief of dry and chesty coughs

Difflam ™

Difflam range of products relieve painful conditions of the mouth and throat.

Allergy A to ZEP

A range of allergy medications designed to relieve different allergy symptoms.